Etavopivat

2026年9月，诺和诺德在资本市场日上抛出了一份充满野心的蓝图：到2030年推出五款以上重磅炸弹级产品，到2035年实现超过1500亿丹麦克朗（约230亿美元）的风险调整后管线销售额，并在肥胖症和糖尿病之外建立至少五个III期项目。 目标足够宏大，方向足够清晰。但市场的回应是一记冷拳，演示结束后，诺和诺德股价下跌7%。 这7%的跌幅，精准揭示了投资者最深的疑虑：诺和诺德正在试图戒掉对司美格鲁肽的依赖，但戒断反应已经开始显现，而替代品的成色尚未经过终局检验。 CagriSema的“及格线” CagriSema是诺和诺德肥胖管线中最接近商业化的资产，也是检验其“后司美格鲁肽时代”成色的第一块试金石。 2026年9月公布的III期数据显示，CagriSema在超重或肥胖人群中68周实现21%的减重效果，安慰剂组为2%。在2型糖尿病患者中，CagriSema 1mg剂量实现约12.4%的平均减重，优于替尔泊肽5mg剂量的9.1%。诺和诺德已提交该药在美国用于体重管理的上市申请，预计2026年第四季度获得监管决定。 数字本身不差，但放在竞争坐标系中，21%的减重幅度处于一个微妙的位置。 BMO分析师Evan Seigerman指出，这些发现并没有乍看起来那么有影响力。在肥胖症领域，替尔泊肽已被证明优于更高剂量的CagriSema。换句话说，CagriSema的“及格线”是由替尔泊肽划定的，而诺和诺德交出的答卷并未超越这条线。 CagriSema的战略价值在于“补位”而非“颠覆”。它是司美格鲁肽与卡格列肽的复方制剂，本质上是诺和诺德在既有GLP-1资产基础上的机制叠加，而非全新分子实体的突破。这种“渐进式创新”在商业上并非没有价值——它可以延长诺和诺德在肥胖症领域的产品生命周期，为更早期的管线争取时间。但它无法回答一个更根本的问题：当礼来的下一代产品在疗效上持续领先，诺和诺德的肥胖症业务能否守住定价权和市场份额？ CagriSema的获批将是诺和诺德2026年最重要的监管节点之一。但如果它的商业定位仅仅是“司美格鲁肽的升级版”而非“替尔泊肽的挑战者”，那么诺和诺德在肥胖症赛道的竞争态势不会因这款产品的上市而发生根本性改变。 从胰淀素到三重激动剂，能否织出第二曲线？ 诺和诺德显然清楚单一产品的局限性。其在肥胖症领域的管线布局，呈现出一种“多机制、多阶段、多来源”的广撒网策略。 胰淀素通路是诺和诺德最集中的押注方向。 除了CagriSema，卡格列肽单药正在推进III期；另一款GLP-1/胰淀素激动剂zenagamtide（原名amycretin）正在开发注射和口服两种剂型，覆盖肥胖症和2型糖尿病。诺和诺德对胰淀素通路的系统性布局，反映了一个判断：GLP-1单机制的天花板已经可见，联合或替代机制是打开下一阶段疗效空间的关键。 外部引进正在成为管线扩张的主要来源。 从联邦制药授权引进的三重激动剂UBT251（GLP-1/GIP/胰高血糖素），从Septerna引进的临床前资产，从Lexicon Pharmaceuticals引进的口服ACSL5抑制剂，从Kallyope购买的三个肥胖症项目，以及从恒瑞医药引进的HRS-1596（GLP-1R/GIPR双重激动剂，具有每周一次口服给药的潜力），诺和诺德的肥胖管线正在以“自研+引进”双轮驱动的方式快速膨胀。 2026年2月与Vivtex签署协议，开发肥胖症和糖尿病生物候选药物的口服递送；9月授权引进Nanexa的PharmaShell原子层沉积技术平台，用于治疗肽药物。这两笔交易指向同一个目标：将传统上必须注射的多肽药物转化为口服制剂，从而在便利性维度上建立差异化优势。 这套“广撒网”策略的逻辑是清晰的：在肥胖症领域，诺和诺德无法承受在任何一个有潜力的机制方向上缺席的代价。 但广撒网也意味着资源分散和不确定性叠加。从恒瑞引进的HRS-1596尚处于I期临床准备阶段，从Kallyope购买的三个项目均处于早期开发，UBT251的III期数据尚未读出——这些资产的临床价值兑现，需要数年时间和持续的资金投入。 多元化的代价 诺和诺德“在肥胖症和糖尿病之外建立至少五个III期项目”的目标，在2026年遭遇了一次严重的现实检验。 Ziltivekimab是一款靶向IL-6介导炎症的抗体，旨在降低心血管事件风险。2026年7月，该资产在一项III期试验中未能降低心血管事件风险；9月，诺和诺德终止了该资产的其他两项研究。分析师开始质疑IL-6靶点在慢性心血管疾病中是否有效。CEO Doustdar表示公司并未放弃心血管领域，但管线中其余四个心血管资产大多处于早期阶段，“至少五个III期项目”的目标，在心血管领域至少暂时失去了最接近兑现的候选者。 肝病领域的进展则更为扎实。诺和诺德通过2025年以52亿美元收购Akero Therapeutics获得efruxifermin，正在开发用于MASH（代谢功能障碍相关脂肪性肝炎）。此外，司美格鲁肽已获批作为注射剂用于MASH，口服制剂的上市申请也已提交。MASH是一个患者基数庞大、治疗选择有限的领域，efruxifermin的差异化机制（FGF21类似物）如果能在III期得到验证，将成为诺和诺德在代谢疾病之外最重要的增长驱动力之一。 血液和内分泌疾病领域，诺和诺德的布局更为成熟。用于A型血友病的双特异性抗体FVIIIa模拟物denecimig已提交监管批准；用于镰状细胞病的etavopivat在2026年4月III期试验取得积极顶线结果，达到减少血管闭塞危象和改善血红蛋白反应两个共同主要终点，计划2026年下半年提交监管申请。这两款药物虽然市场体量不及肥胖症，但竞争格局相对清晰，商业化路径更为确定。 多元化的本质不是分散风险，而是在正确的领域建立足以对冲核心产品衰退的增长极。 诺和诺德在肝病和血液领域的进展，为其“五个III期”目标提供了实质性支撑；但心血管领域的挫折提醒市场，从核心特许经营权向新治疗领域扩张的成功率，远低于在既有领域内做深做透。 结语 诺和诺德的2035年230亿美元目标，是一份方向明确但兑现路径充满变量的战略蓝图。 CagriSema即将迎来FDA决定，但它面对的是一个由替尔泊肽划定标准的竞争环境；肥胖管线通过自研和引进快速膨胀，但多数资产仍处于早期阶段；肝病和血液领域提供了多元化的实质性进展，心血管领域的挫折则暴露了扩张的风险。AI合作（OpenAI、Anthropic、Orbis）被列为研发生产力的赋能因素，但其长期价值取决于能否转化为更好的药物和更快的开发时间表，而非捷径。 资本市场日后的7%跌幅，是投资者用脚投票的结果。它传递的信号并非对诺和诺德战略方向的否定，而是对“方向已定、兑现未至”这一中间状态的焦虑。诺和诺德仍拥有可观的科学和商业能力，但它现在必须证明三件事：下一代肥胖症药物能够与礼来正面竞争；代谢疾病之外的投资能够产生有意义的新增长；管线能够经受住药物开发中不可避免的挫折。 戒掉司美格鲁肽依赖，需要的不是一份2035年的目标清单，而是一个接一个经得起头对头检验的临床数据读出。 在生物制药行业，战略的成色从来不取决于资本市场日的演示文稿，而取决于下一个III期试验的顶线结果。诺和诺德的方向已经明确，但通往230亿美元的路，才刚刚开始铺设。 参考资料 Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035 本期图片素材来源：https://unsplash.com/ 往期阅读推荐 点击标题跳转到对应原文 01-《5年175亿美元！13家AI制药公司谁能跑出临床验证？》 02-《tau降85%！这款RNAi药物能破阿尔茨海默病困局吗？》 03-《生物医药人才变动信息》（26年10月10日-10月16日） 04-《生物医药领域融资动态及行业观察》（26年10月09日-10月15日） 05-《MNC接连下注，大环药物这次真站上风口了？》 06-《BMS能填上2028专利悬崖的百亿缺口吗？》 07-《甄育资本生物医药买方需求明细清单》 08-《生物医药人才变动信息》（26年09月28日-10月09日） 09-《生物医药领域融资动态及行业观察》（26年09月24日-10月27日） More exciting content is continuously being updated. 免责声明 “会会药咖”文章旨在传递信息，我们力求提供准确资讯，但对其完整性、准确性不做担保，所有内容仅供参考，不构成任何商业或医疗建议，使用者自行承担风险。如对内容有疑议，请及时联系我们。本声明与法律法规冲突时，以法律法规为准。 会会药咖建群啦！ 分 享 生 物 医 药 行 业 讯 息  、 专 业 知 识 扫 码 审 核 进 群 Cooperation 如有合作需求，欢迎随时与我们联系~ 会 务 合 作 微  信丨柏鳌创新 电  话丨18000558050 媒 体 合 作 微  信丨会会药咖 电  话丨15828041131 喜欢这篇文章，别忘了点一点文章末尾的“点赞”“分享”“喜欢”。 把我们设为星标，让我们之间的深度链接不会错过。

Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in advancing novel therapeutics from discovery and translational research through global clinical development, regulatory interactions and commercialization planning. "We are delighted to welcome Cameron to AN2 Therapeutics," said Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics. "Cameron's extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline. His scientific rigor, patient-centric mindset and proven leadership across both emerging biotechnology companies and large pharmaceutical organizations make him an outstanding addition to our executive team.” Easom continued, “I would also like to thank Dr. George H. Talbot, Co-Founder and Senior Scientific Advisor of AN2 Therapeutics, for his leadership of our clinical programs during the last two years and his enormous contributions from day one of AN2. We are grateful for his continued commitment to the Company during the transition and as a strategic advisor going forward." Most recently, Dr. Trenor served as Chief Medical Officer of Cellarity, where he led the establishment of its medical organization through its transition to a clinical-stage biotechnology company. As Chief Medical Officer, he oversaw development of Cellarity's lead program, including the company's first IND submission and initiation of a global first-in-human clinical study. Prior to Cellarity, Dr. Trenor served as Executive Medical Director at Forma Therapeutics, which was acquired by Novo Nordisk, where he led global clinical development activities for etavopivat across multiple indications and supported the program's advancement from early clinical development into Phase 3. Earlier in his career, Dr. Trenor led clinical and translational programs in hematology and rare diseases at Novartis Institutes for BioMedical Research. He remains a practicing pediatric hematologist-oncologist at Boston Children's Hospital and has authored approximately 60 peer-reviewed research publications. Dr. Trenor received a B.S. in Biology from Tufts University, an M.D. from the University of Tennessee College of Medicine and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. He completed his residency and fellowship training through Boston Children's Hospital, Boston Medical Center and Dana-Farber Cancer Institute and is board-certified in Pediatric Hematology-Oncology. About AN2 Therapeutics AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical oncology candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the Company’s planned initiation of three Phase 2 trials in 2026 and declaration of two preclinical candidates and the potential impact of new personnel on the outcome of the Company’s programs. These statements are based on AN2’s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: AN2’s ability to implement its plans for its internal boron chemistry platform and pipeline programs; timely enrollment of patients in AN2’s clinical trials and investigator-initiated clinical trials; AN2’s ability to procure sufficient supply of its product candidates for its clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary, or expected results; the ability of particular preclinical models in non-human primates to predict safety and efficacy in humans; significant adverse events, toxicities, or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; AN2’s ability to obtain, maintain, or protect intellectual property rights related to its current and future product candidates; implementation of AN2’s strategic plans for its business and product candidates; the sufficiency of AN2’s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts and other risks, including those described under the heading “Risk Factors” in AN2’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (SEC). These filings, when made, are available on the investor relations section of AN2’s website at and on the SEC’s website at . Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law. Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer l.day@an2therapeutics.com INVESTOR AND MEDIA CONTACT: Anne Bowdidge ir@an2therapeutics.com